© 2021 MJH Life Sciences and OncLive. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2021 MJH Life Sciences™ and OncLive. All rights reserved.
Reactions to treatment advances and new FDA approvals in prostate cancer, and insight regarding the valuable role that precision medicine plays in genitourinary oncology.
August 16th 2021
A panel of physicians who work in the field of genitourinary oncology comment on the evolving role of precision medicine in advanced prostate cancer.
Dr Scott T. Tagawa comments on the pros and cons of liquid and tissue biopsies used to assess patients with advanced prostate cancer.
August 23rd 2021
A discussion regarding the use of PSMA PET imaging to detect phenotypic biomarkers that may simplify approaches to precision medicine in advanced prostate cancer.
An interpretation of the OSPREY study of 18F-DCFPyL injection in patients with high-risk prostate cancer and implications of its use.
August 30th 2021
A discussion regarding use of the PSMA-targeted 18F-DCFPyL PET/CT to assess patients with suspected recurrence of prostate cancer based on data revealed by the CONDOR trial.
Treatment Advances in mCSPC
September 7th 2021
The rationale for treating metastatic castration-sensitive prostate cancer with androgen deprivation therapy as monotherapy as the field advances with newer combination approaches.
Potential implications for treating metastatic castration-sensitive prostate cancer with triple therapy based on recently reported data.
September 13th 2021
Recommendations for integrating treatment advances in metastatic castration-sensitive prostate cancer into everyday practice.
Implications of treating patients with metastatic castration-sensitive prostate cancer with relugolix, an oral GnRH antagonist.
September 20th 2021
An overview of drug approvals for nonmetastatic castration-resistant prostate cancer (CRPC), and discussion regarding the potential utility of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) to guide treatment decisions.
An in-depth discussion regarding experience treating nonmetastatic castration-resistant prostate cancer (CRPC) with apalutamide, enzalutamide, and darolutamide, and factors that impact treatment selection.